This Article Full Text Full Text (PDF) All Versions of this Article: 45/2/246    most recent 01.HYP.0000151620.17905.eev1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van den Born, B. J. H. Articles by van Montfrans, G. A. Search for Related Content PubMed PubMed Citation Articles by van den Born, B. J. H. Articles by van Montfrans, G. A. Pubmed/NCBI databases Medline Plus Health Information Kidney Failure Vascular Diseases Related Collections Other hypertension Clinical Studies

(Hypertension. 2005;45:246.)
© 2005 American Heart Association, Inc.

Scientific Contributions

Microangiopathic Hemolysis and Renal Failure in Malignant Hypertension

From the Departments of Internal Medicine (B.J.H.v.d.B., U.P.F.H., R.P.K., G.A.v.M.) and Pharmacology and Pharmacotherapy (R.P.K.), Academic Medical Centre, Amsterdam, the Netherlands.

Correspondence to B.J.H. van den Born, Department of Internal Medicine, Academic Medical Centre, Meibergdreef 9, Room F4-222, PO Box 22660, 1100 DD, Amsterdam, the Netherlands. E-mail b.j.vandenborn{at}amc.uva.nl

Renal dysfunction is an important cause of morbidity and mortality in patients with malignant hypertension. Microangiopathic hemolysis (MAHA) related to malignant hypertension may cause renal insufficiency by obstruction of interlobular arteries. We hypothesized that the presence of MAHA is an important indicator of renal dysfunction and recovery in malignant hypertension. We retrospectively analyzed 97 patients admitted between April 1994 and April 2004 with malignant hypertension. MAHA was defined as a low platelet count (<150x10⁹/L) with either an elevated lactic dehydrogenase (>220 U/L) or presence of schistocytes. MAHA was present in 26 of 97 patients (27%). Serum creatinine levels at admission were significantly higher in those with than in those without MAHA: median serum creatinine 690 µmol/L (interquartile range [IQR] 394 to 1105) and 120 µmol/L (IQR 82 to 211), respectively (P<0.01). Macroalbuminuria was present in 88% with versus 41% without MAHA (P<0.01). Patients with MAHA were more often black (73%; P<0.01) and had higher systolic blood pressure (mean 242 mm Hg versus 225 mm Hg; P<0.01). Dialysis was needed in 15 patients with MAHA (58%) versus 2 patients (3%) without MAHA. In 6 patients with MAHA, dialysis could be stopped. Cox regression analysis showed that MAHA and systolic blood pressure were the most important indicators of renal improvement during follow-up, with a hazard ratio of 0.24 (95% confidence interval [CI], 0.08 to 0.75; P=0.01) and 1.02 per mm Hg increase in systolic blood pressure (95% CI, 1.01 to 1.05; P=0.01). In conclusion, MAHA is an important indicator of renal insufficiency and recovery in patients with malignant hypertension.

Key Words: hypertension, malignant • kidney • blacks

This article has been cited by other articles:

				C. P. Denton, G. Lapadula, L. Mouthon, and U. Muller-Ladner Renal complications and scleroderma renal crisis Rheumatology, June 1, 2009; 48(suppl_3): iii32 - iii35. [Abstract] [Full Text] [PDF]

				B.-J. H. van den Born and G. A. van Montfrans Response to the Malignant Hypertension-Thrombotic Microangiopathy Link Hypertension, October 1, 2008; 52(4): e33 - e33. [Full Text] [PDF]

				B.-J. H. van den Born, N. V. van der Hoeven, E. Groot, P. J. Lenting, J. C.M. Meijers, M. Levi, and G. A. van Montfrans Association Between Thrombotic Microangiopathy and Reduced ADAMTS13 Activity in Malignant Hypertension Hypertension, April 1, 2008; 51(4): 862 - 866. [Abstract] [Full Text] [PDF]

				H. Penn, A.J. Howie, E.J. Kingdon, C.C. Bunn, R.J. Stratton, C.M. Black, A. Burns, and C.P. Denton Scleroderma renal crisis: patient characteristics and long-term outcomes QJM, August 1, 2007; 100(8): 485 - 494. [Abstract] [Full Text] [PDF]